Knight Therapeutics (TSE:GUD) Shares Down 1% – Time to Sell?

Knight Therapeutics Inc. (TSE:GUD)’s stock price was down 1% on Friday . The stock traded as low as C$5.88 and last traded at C$5.91. Approximately 20,757 shares traded hands during mid-day trading, a decline of 69% from the average daily volume of 66,793 shares. The stock had previously closed at C$5.97.

Knight Therapeutics Price Performance

The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The company has a 50-day simple moving average of C$6.03 and a 200-day simple moving average of C$6.09. The company has a market cap of C$586.80 million, a price-to-earnings ratio of -147.75, a PEG ratio of -1,013.50 and a beta of -0.01.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings data on Thursday, November 6th. The company reported C($0.04) earnings per share for the quarter. The business had revenue of C$122.63 million for the quarter. Knight Therapeutics had a negative return on equity of 4.04% and a negative net margin of 8.81%. As a group, research analysts predict that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.